Clinical trials: Nerve Sheath Tumors
Vestibular Schwannoma, Acoustic Neuroma
Auditory Nerve Test System During Vestibular Schwannoma Resection
The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for…
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Sensorineural Hearing Loss, Asymmetric Sensorineural Hearing Loss
- Trial name
- ANTS (NCT04241679)
- Testing
- Auditory Nerve Test System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Neuroma
ALGRX 4975 in the Treatment of Patients With Morton's Neuroma
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma.
- Trial name
- NCT00130962
- Testing
- ALGRX 4975
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- AlgoRx Pharmaceuticals
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neurofibromatosis Type 1, Precancerous Condition
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
RATIONALE: New imaging procedures such as fludeoxyglucose F 18 positron emission tomography (FDG-PET) and magnetic resonance (MR) perfusion imaging may improve the ability to detect disease progression, help doctors predict a…
- Trial name
- NCT00060008
- Testing
- fludeoxyglucose F 18, gadopentetate dimeglumine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital of Philadelphia
Neurofibromatosis 1, Neurofibroma, Plexiform
Real-World Treatment Study of Koselugo (Selumetinib)
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and…
- Trial name
- NCT06360406
- Where
- 12 sites in South Korea
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Vestibular Schwannoma
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
Vestibular schwannomas (VS) arise from the vestibulocochlear (hearing and balance) nerve, located at the base of the brain. Although benign, VS can enlarge over time, resulting in debilitating symptoms; therefore, surgical…
- Trial name
- NCT04057976
- Testing
- Probabilistic diffusion tensor tractography
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- King's College Hospital NHS Trust
Malignant Peripheral Nerve Sheath Tumour (MPNST)
A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery
This is phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in subjects with metastatic or locally advanced/unresectable or metastatic malignant peripheral nerve sheath tumour (MPNST).
- Trial name
- NCT02691026
- Testing
- Pembrolizumab
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Oslo University Hospital
Vestibular Schwannoma
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma…
- Trial name
- NCT04351373
- Testing
- Fluorescein Sodium, YELLOW560 filter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Neurofibromatosis 1
Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
The purpose of this study is to find blood plasma based biomarkers of disease progression in neurofibromatosis type 1 (NF1). NF1 is associated with the development of benign cutaneous tumors as well as a variety of malignancies.
- Trial name
- NCT02680431
- Testing
- Blood sample
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Juha Peltonen
Neurofibromatosis 1, Plexiform Neurofibroma
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib.
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma, NF1
- Trial name
- NCT04954001
- Testing
- FCN-159
- Where
- 14 sites in United States, China and 1 more
- Volunteers
- 160 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Neurofibromatosis 1, Plexiform Neurofibroma
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Background/Rationale: Neurofibromatosis type 1 (NF1) affects about 1 in every 3000 people worldwide. Globally, 30~50% NF1 patients will develop plexiform neurofibromas (PNs), which grow rapidly in early childhood and can cause…
- Trial name
- NCT06379230
- Testing
- This study is purely descriptive study.
- Where
- 5 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Neurofibromatosis Type 1
Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.
The goal of this project is to get more insight into the (neuro)ophthalmological characteristics of children with neurofibromatosis type 1.
- Trial name
- NCT02078401
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00346164
- Testing
- doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 588 people
- Sponsor
- Children's Oncology Group
Vestibular Schwannoma
Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating vestibular function prior to surgery, even if vestibular function is absent according to…
- Trial name
- NCT02415257
- Testing
- Gentamicin
- Where
- Sweden
- Sponsor
- Lund University
Neurofibromatosis Type 1, Tumors of the Central Nervous System
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Objectives 1. Establish an induced pluripotent stem cell (iPSC) bank for phenotypically well-characterized patients with NF1. 2.
- Trial name
- NCT03332030
- Testing
- Collection of Stem Cells
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Roger Packer
Neurofibromatosis 1
Non-invasive Stimulation in Neurofibromatosis Type 1
Intellectual impairments are a significant cause of morbidity in children with birth defects along with long term implication on academic and occupational functioning.
- Trial name
- tDCS is NF1 (NCT03310996)
- Testing
- Transcranial direct current stimulation
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Manchester
Digital Nerve Injury
Vitamin D3 in Sensory Recovery After Digital NERVe Suture (D3NERV).
Digital nerve injuries are frequent in a FESUM center (Federation Européenne des Services d'Urgences Mains), and they need to be repaired in order to reduce the risk of hypoesthesia and to prevent painful neuroma.
- Trial name
- D3NERV (NCT04115982)
- Testing
- Cholecalciferol
- Where
- 3 sites in France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Caen
Neurofibromatosis Type 1 (NF1), NF2-related Schwannomatosis
How Can the Experience of Hospital Outpatient Departments be Improved?
This project aims to improve outpatient departments by working with patients and staff to make these spaces more inclusive for people with sensory challenges (it focuses on people with nerve tumour conditions as they are more…
- Trial name
- NCT07818213
- Testing
- Qualitative data collection activities
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- King's College London
Pain, Pain, Postoperative
Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients
The main objective study is to compare the use of the cryoSPHERE probe to the standard-of-care method for pain management of patients receiving robotic-assisted thoracoscopic surgery, including reductions in opioid pain…
- Trial name
- NCT05276258
- Testing
- cryoSPHERE Ablation, Bupivacaine
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- The Methodist Hospital Research Institute
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as vinblastine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352495
- Testing
- carboplatin, vinblastine sulfate
- Where
- 21 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- Children's Oncology Group